Ibritumobab tiuxetan (Zevalin)

Radiolabeled monoclonal antibody for the treatment of patients with B cell non-Hodgkin’s lymphomas with relapsed or refractory low-grade follicular or transformed B cell NHL, including patients with rituximab refractory follicular disease.

High response rates and durable responses in above lymphomas with a regimen that takes 7-9 days.

Leave a Reply

Your email address will not be published. Required fields are marked *